Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the eleven analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $24.25.
Several equities analysts have recently commented on ARCT shares. Weiss Ratings upgraded Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, April 21st. B. Riley Financial began coverage on Arcturus Therapeutics in a research report on Wednesday, March 18th. They set a “buy” rating and a $22.00 target price for the company.
Get Our Latest Analysis on Arcturus Therapeutics
Arcturus Therapeutics Price Performance
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last released its earnings results on Friday, May 8th. The biotechnology company reported ($0.95) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.08. Arcturus Therapeutics had a negative net margin of 143.80% and a negative return on equity of 36.55%. The company had revenue of $2.06 million for the quarter, compared to analysts’ expectations of $6.30 million. On average, research analysts expect that Arcturus Therapeutics will post -3.99 EPS for the current year.
Institutional Investors Weigh In On Arcturus Therapeutics
Institutional investors have recently added to or reduced their stakes in the stock. ARK Investment Management LLC raised its position in shares of Arcturus Therapeutics by 39.4% during the fourth quarter. ARK Investment Management LLC now owns 2,611,099 shares of the biotechnology company’s stock valued at $16,006,000 after buying an additional 738,378 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Arcturus Therapeutics by 12.9% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,288,935 shares of the biotechnology company’s stock worth $17,671,000 after acquiring an additional 262,347 shares during the last quarter. Amova Asset Management Americas Inc. boosted its position in shares of Arcturus Therapeutics by 12.9% during the first quarter. Amova Asset Management Americas Inc. now owns 2,288,935 shares of the biotechnology company’s stock worth $17,648,000 after acquiring an additional 262,347 shares during the last quarter. Vanguard Group Inc. grew its stake in Arcturus Therapeutics by 4.2% during the third quarter. Vanguard Group Inc. now owns 1,885,605 shares of the biotechnology company’s stock valued at $34,752,000 after acquiring an additional 75,440 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in Arcturus Therapeutics by 112.0% during the third quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock valued at $11,428,000 after acquiring an additional 327,626 shares in the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.
The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.
Featured Articles
- Five stocks we like better than Arcturus Therapeutics
- These Stocks Could Win as Wall Street Looks Beyond AI Software
- D.R. Horton Is Defying the Housing Gloom
- Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire
- Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
